Cuộc họp công bố kết quả kinh doanh quý 2/2026 của ImmuCell (ICCC): Doanh số tăng 11,5%, lên kế hoạch mở rộng công suất
Doanh số quý 2/2026 của ImmuCell tăng 11,5% lên 7,2 triệu USD, trong khi biên lợi nhuận gộp giảm xuống 33,9%. Ban lãnh đạo đã công bố chi tiết kế hoạch mở rộng năng lực sản xuất trị giá 8 triệu USD.
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).